# Mizuki Nishino

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mizuki-nishino/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,926 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 82 |
| i10-index | 226 |
| Last Known Institution | Brigham and Women's Hospital |
| OpenAlex ID | https://openalex.org/A5069854182 |
| ORCID iD | 0000-0003-0275-0502 |
| Works | 830 |

## Researcher papers

Showing 12 of 18.

- [<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma](https://scholariq.org/papers/i-stk11-lkb1-i-mutations-and-pd-1-inhibitor-resistance-in-i-kras-i-mutant-lung/)
- [Monitoring immune-checkpoint blockade: response evaluation and biomarker development](https://scholariq.org/papers/monitoring-immune-checkpoint-blockade-response-evaluation-and-biomarker/)
- [Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer](https://scholariq.org/papers/incidence-of-programmed-cell-death-1-inhibitor-related-pneumonitis-in-patients/)
- [Lung Volumes and Emphysema in Smokers with Interstitial Lung Abnormalities](https://scholariq.org/papers/lung-volumes-and-emphysema-in-smokers-with-interstitial-lung-abnormalities/)
- [Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements](https://scholariq.org/papers/developing-a-common-language-for-tumor-response-to-immunotherapy-immune-related/)
- [PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course](https://scholariq.org/papers/pd-1-inhibitor-related-pneumonitis-in-advanced-cancer-patients-radiographic/)
- [Association Between Interstitial Lung Abnormalities and All-Cause Mortality](https://scholariq.org/papers/association-between-interstitial-lung-abnormalities-and-all-cause-mortality/)
- [<i>MUC5B</i> Promoter Polymorphism and Interstitial Lung Abnormalities](https://scholariq.org/papers/i-muc5b-i-promoter-polymorphism-and-interstitial-lung-abnormalities/)
- [A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response](https://scholariq.org/papers/a-murine-lung-cancer-co-clinical-trial-identifies-genetic-modifiers-of/)
- [Institutional implementation of clinical tumor profiling on an unselected cancer population](https://scholariq.org/papers/institutional-implementation-of-clinical-tumor-profiling-on-an-unselected-cancer/)
- [Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels](https://scholariq.org/papers/association-of-high-tumor-mutation-burden-in-non-small-cell-lung-cancers-with/)
- [Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status](https://scholariq.org/papers/diminished-efficacy-of-programmed-death-ligand-1-inhibition-in-stk11-and-keap1/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)

## Researcher university

- [Brigham and Women's Hospital](https://scholariq.org/institutions/brigham-and-women-s-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.